TapewireFind a company

person · Reporting owner

PATIENCE JOHN

Disclosed activity across 3 companies

Tapewire entity
33236
SEC CIK
0001021413

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Accelerate Diagnostics, IncAXDX · Entity 78156DirectorDecember 03, 2024December 03, 2024
BIODESIX INCBDSX · Entity 6053Director · ChairmanSeptember 30, 2026October 03, 2026
STERICYCLE INCSRCL · Entity 80873DirectorMay 23, 2018May 25, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Accelerate Diagnostics, Inc

Report date December 03, 2024 · Filed December 03, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy John Patience Living Trust dated 7/23/1993653,224 Reported balance After 2024-12-03 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2024-12-03 · Purchase · Acquired 200,000 · Balance 653,224

F1: Represents shares purchased by the reporting person from Jack Schuler, a member of the issuer's board of directors, in a private transaction.

F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.

Common StockSEC Table I · non-derivativeIndirectBy IRA3,941 Reported balance Holding disclosure · report date 2024-12-03 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 3,941

Common StockSEC Table I · non-derivativeIndirectBy Patience Enterprises LP214,046 Reported balance Holding disclosure · report date 2024-12-03 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 214,046

F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares purchased by the reporting person from Jack Schuler, a member of the issuer's board of directors, in a private transaction.

F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.

F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

BIODESIX INC

Report date September 30, 2026 · Filed October 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect26,743 Reported balance After 2026-09-30 transaction · row 1
1 source row

Row 1 · 2026-09-30 · Exercise / conversion · Acquired 1,360 · Balance 26,743

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect1,361 Reported balance After 2026-09-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-09-30 · Exercise / conversion · Disposed 1,360 · Balance 1,361

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

F4: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Common StockSEC Table I · non-derivativeIndirectBy Patience Enterprises LP107,664 Reported balance Holding disclosure · report date 2026-09-30 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 107,664

F2: The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectBy John Patience Living Trust dated 7/23/1993241,480 Reported balance Holding disclosure · report date 2026-09-30 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 241,480

F3: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).

Common StockSEC Table I · non-derivativeIndirectBy Spouse2,649 Reported balance Holding disclosure · report date 2026-09-30 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 2,649

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

F2: The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F3: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).

F4: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

STERICYCLE INC

Report date May 23, 2018 · Filed May 25, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct3,878 Reported balance After 2018-05-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-05-23 · Grant · Acquired 1,970 · Balance 3,878

F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Filing footnotes · ownership attribution and instrument terms

F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 07, 2020 Filed Dec 10, 2020 02:39 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionStock Options (Right to Buy) · Derivative 23,440 $0.00 Strike: $6.83 $0.00
Disclosure

SEC source: 0000905148-20-001262 · form4.xml · derivative · entry 7

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,718

Underlying: Common Stock · 23,440 shares

Expires 2030-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option vests in 12 successive, equal monthly installments measured from April 1, 2020.

Read SEC document
December 07, 2020 Filed Dec 10, 2020 02:39 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionStock Options (Right to Buy) · Derivative 35,157 $0.00 Strike: $6.83 $0.00
Disclosure

SEC source: 0000905148-20-001262 · form4.xml · derivative · entry 6

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1

Underlying: Common Stock · 35,157 shares

Expires 2029-07-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option vested in 12 successive, equal monthly installments measured from April 1, 2019.

Read SEC document
December 07, 2020 Filed Dec 10, 2020 02:39 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 23,440 $6.83 $160,095.20
Disclosure

SEC source: 0000905148-20-001262 · form4.xml · nonDerivative · entry 2

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 07, 2020 Filed Dec 10, 2020 02:39 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 35,157 $6.83 $240,122.31
Disclosure

SEC source: 0000905148-20-001262 · form4.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 Conversion3% Convertible Debt due June 2021 · Derivative Not disclosed $0.00 Strike: $14.40 $900,000.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 21

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 0

Underlying: Common Stock · 64,416 shares

Expires 2021-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 Conversion3% Convertible Debt due June 2021 · Derivative Not disclosed $0.00 Strike: $14.40 $1,150,000.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 20

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 0

Underlying: Common Stock · 81,600 shares

Expires 2021-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries H Preferred Stock · Derivative 4,182,413 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 18

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 0

Underlying: Common Stock · 704,596 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries G Preferred Stock · Derivative 6,711,816 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 17

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 0

Underlying: Common Stock · 1,130,715 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries G Preferred Stock · Derivative 957,114 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 16

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 0

Underlying: Common Stock · 161,242 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries F Preferred Stock · Derivative 3,055,837 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 15

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 0

Underlying: Common Stock · 514,806 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries F Preferred Stock · Derivative 3,205,681 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 14

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 0

Underlying: Common Stock · 540,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries E Preferred Stock · Derivative 1,484,624 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 13

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 0

Underlying: Common Stock · 250,109 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries E Preferred Stock · Derivative 809,200 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 12

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 0

Underlying: Common Stock · 136,323 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries D Preferred Stock · Derivative 2,932,534 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 11

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 0

Underlying: Common Stock · 494,033 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries D Preferred Stock · Derivative 250,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 10

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 0

Underlying: Common Stock · 42,117 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries C Preferred Stock · Derivative 666,666 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 9

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 0

Underlying: Common Stock · 112,311 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries B-1 Preferred Stock · Derivative 1,250,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 8

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 0

Underlying: Common Stock · 245,041 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers gave effect to such conversion. The B-1 Preferred Stock had no expiration date.

F4 · derivative.exercise_date: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers gave effect to such conversion. The B-1 Preferred Stock had no expiration date.

F4 · derivative.expiration_date: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers gave effect to such conversion. The B-1 Preferred Stock had no expiration date.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionSeries B Preferred Stock · Derivative 1,454,545 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 7

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 0

Underlying: Common Stock · 245,042 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 PurchaseCommon Stock 30,000 $18.00 $540,000.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 6

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 30,000

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionCommon Stock 64,416 $14.40 $927,590.40
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 5

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 2,811,431

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionCommon Stock 81,600 $14.40 $1,175,040.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 4

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 1,910,968

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionCommon Stock 245,041 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 3

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 2,747,015

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers gave effect to such conversion. The B-1 Preferred Stock had no expiration date.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionCommon Stock 2,501,974 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 2

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 2,501,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993).

Read SEC document
October 30, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 ConversionCommon Stock 1,829,368 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 1,829,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
June 23, 2020 Filed Nov 3, 2020 23:25 UTC BIODESIX INC BDSX · Entity 6053 Grant3% Convertible Debt due June 2021 · Derivative Not disclosed $0.00 $150,000.00
Disclosure

SEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 19

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 1,150,000

Underlying: Common Stock · 10,527 shares

Expires 2021-06-30

F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest.

F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest.

F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 12:21 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 GrantStock Option (right to buy) · Derivative 13,779 $0.00 Strike: $8.33 $0.00
Disclosure

SEC source: 0001628280-20-004571 · wf-form4_158593084397620.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,779

Underlying: Common Stock · 13,779 shares

Expires 2030-04-01

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, with the first installment vesting on May 1, 2020.

Read SEC document
March 24, 2020 Filed Mar 26, 2020 15:35 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 5,000 $6.83 $34,150.00
Disclosure

SEC source: 0001628280-20-004093 · wf-form4_158525130138977.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Trust dated 7/23/1993

Disclosed balance after: 4,196,211

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.81 to $6.85, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Read SEC document
March 24, 2020 Filed Jul 31, 2020 18:16 UTC Amendment Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 5,000 $6.83 $34,150.00
Disclosure

SEC source: 0001628280-20-011379 · wf-form4a_159623377007067.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Living Trust dated 7/23/1993

Disclosed balance after: 4,300,481

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.81 to $6.85, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · balance_after: Due to a clerical error, the reported shares owned indirectly by the reporting person through the John Patience Living Trust dated 7/23/1993 (the "Trust") has been adjusted to correct an understatement of 104,270 shares. The 104,270 shares represent (i) 59,600 shares acquired by the Trust on May 2, 2014, which were previously reported in the reporting person's Form 4 filed May 2, 2014 and inadvertently omitted in subsequent filings; (ii) 20,000 shares acquired by the Trust on December 1, 2016, which were incorrectly reported as acquired directly by the reporting person in the reporting person's Form 4 filed December 7, 2016 and in subsequent filings; and (iii) 24,670 shares acquired by the Trust on December 13, 2016, which were incorrectly reported as acquired directly by the reporting person in the reporting person's Form 4 filed December 14, 2016 and in subsequent filings.

Read SEC document
April 01, 2019 Filed Mar 27, 2020 21:04 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 GrantStock Option (right to buy) · Derivative 12,290 $0.00 Strike: $21.02 $0.00
Disclosure

SEC source: 0001628280-20-004263 · wf-form4_158535748088342.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,290

Underlying: Common Stock · 12,290 shares

Expires 2029-04-01

F1 · date: This Form 4 was inadvertently not filed within the required time following the transaction date of April 1, 2019.

F2 · derivative.exercise_date: The option vests in twelve equal monthly installments, with the first installment vesting on May 1, 2019.

Read SEC document
November 08, 2018 Filed Nov 13, 2018 21:40 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 10,000 $14.96 $149,600.00
Disclosure

SEC source: 0001144204-18-059492 · tv506947_4.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Defined Benefit Pension Plan

Disclosed balance after: 39,411

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.96 to $15.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each separate price within the range.

Read SEC document
May 23, 2018 Filed May 24, 2018 16:51 UTC STERICYCLE INC SRCL · Entity 80873 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 7,105 $0.00 Strike: $58.82 $0.00
Disclosure

SEC source: 0001692742-18-000076 · edgardoc.xml · derivative · entry 4

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,105 shares

Expires 2018-05-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 23, 2018 Filed May 24, 2018 16:51 UTC STERICYCLE INC SRCL · Entity 80873 SaleCommon Stock 6,624 $63.15 $418,281.09
Disclosure

SEC source: 0001692742-18-000076 · edgardoc.xml · nonDerivative · entry 2

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,110

Read SEC document
May 23, 2018 Filed May 24, 2018 16:51 UTC STERICYCLE INC SRCL · Entity 80873 Exercise / conversionCommon Stock 7,105 $58.82 $417,916.10
Disclosure

SEC source: 0001692742-18-000076 · edgardoc.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,734

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 23, 2018 Filed May 25, 2018 16:08 UTC STERICYCLE INC SRCL · Entity 80873 GrantRestricted Stock Units · Derivative 1,970 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001692742-18-000090 · edgardoc.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,878

Underlying: Common Stock · 1,970 shares

Expires not disclosed

F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Read SEC document
April 30, 2018 Filed May 2, 2018 17:19 UTC STERICYCLE INC SRCL · Entity 80873 GrantRestricted Stock Units · Derivative 170 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001179110-18-006059 · edgar.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,078

Underlying: Common Stock · 170 shares

Expires not disclosed

F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Read SEC document
April 01, 2018 Filed Apr 3, 2018 15:13 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 GrantStock Option (right to buy) · Derivative 9,476 $0.00 Strike: $22.85 $0.00
Disclosure

SEC source: 0001144204-18-018911 · tv490260_4.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,476

Underlying: Common Stock · 9,476 shares

Expires 2028-04-01

F1 · derivative.exercise_date: The option vests in 12 equal monthly installments, with the first installment vesting on May 1, 2018.

Read SEC document
January 31, 2018 Filed Feb 1, 2018 17:00 UTC STERICYCLE INC SRCL · Entity 80873 GrantRestricted Stock Units · Derivative 132 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001692742-18-000012 · edgardoc.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,908

Underlying: Common Stock · 132 shares

Expires not disclosed

F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Read SEC document
November 07, 2017 Filed Nov 9, 2017 15:00 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 20,000 $18.75 $375,000.00
Disclosure

SEC source: 0001144204-17-057662 · tv479096_4.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Trust dated 7/23/1993

Disclosed balance after: 4,191,211

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.73 to $18.75, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
November 06, 2017 Filed Nov 8, 2017 15:03 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 38,700 $18.61 $720,207.00
Disclosure

SEC source: 0001144204-17-057234 · tv478969_4.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Trust dated 7/23/1993

Disclosed balance after: 4,171,211

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.50 to $18.63, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
October 31, 2017 Filed Nov 1, 2017 18:22 UTC STERICYCLE INC SRCL · Entity 80873 GrantRestricted Stock Units · Derivative 141 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001692742-17-000056 · edgardoc.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,776

Underlying: Common Stock · 141 shares

Expires not disclosed

F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.

Read SEC document
July 31, 2017 Filed Aug 1, 2017 17:53 UTC STERICYCLE INC SRCL · Entity 80873 GrantRestricted Stock Units · Derivative 129 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001692742-17-000049 · edgardoc.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,635

Underlying: Common Stock · 129 shares

Expires not disclosed

F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer.

F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer.

Read SEC document
May 25, 2017 Filed May 26, 2017 16:36 UTC STERICYCLE INC SRCL · Entity 80873 Exercise / conversionRestricted Stock Units · Derivative 495 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0001692742-17-000030 · edgardoc.xml · derivative · entry 3

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 495 shares

Expires 2017-05-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date.

F1 · price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date.

F1 · derivative.exercise_date: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date.

F1 · derivative.expiration_date: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date.

Read SEC document
May 25, 2017 Filed May 26, 2017 16:36 UTC STERICYCLE INC SRCL · Entity 80873 Exercise / conversionCommon Stock 495 Not disclosed Not disclosed
Disclosure

SEC source: 0001692742-17-000030 · edgardoc.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,629

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date.

Read SEC document
May 24, 2017 Filed May 26, 2017 16:36 UTC STERICYCLE INC SRCL · Entity 80873 GrantRestricted Stock Units · Derivative 1,506 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001692742-17-000030 · edgardoc.xml · derivative · entry 4

PATIENCE JOHN · CIK 0001021413 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,506

Underlying: Common Stock · 1,506 shares

Expires not disclosed

F2 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer.

F2 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer.

Read SEC document
April 01, 2017 Filed Apr 4, 2017 19:07 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 GrantStock Option (right to buy) · Derivative 11,721 $0.00 Strike: $24.20 $0.00
Disclosure

SEC source: 0001144204-17-018992 · v463574_4.xml · derivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,721

Underlying: Common Stock · 11,721 shares

Expires 2027-04-01

F1 · derivative.exercise_date: The option vests in 12 equal monthly installments, with the first installment vesting on May 1, 2017.

Read SEC document
January 09, 2017 Filed Jan 10, 2017 19:31 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 39,500 $19.00 $750,500.00
Disclosure

SEC source: 0001144204-17-001696 · v456704_4.xml · nonDerivative · entry 2

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Patience Enterprises LP

Disclosed balance after: 2,110,662

F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
January 09, 2017 Filed Jan 10, 2017 19:31 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 PurchaseCommon Stock 13,200 $19.00 $250,800.00
Disclosure

SEC source: 0001144204-17-001696 · v456704_4.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Patience Trust dated 7/23/1993

Disclosed balance after: 4,132,511

Read SEC document
December 13, 2016 Filed Dec 14, 2016 16:35 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 Exercise / conversionStock Option (right to buy) · Derivative 24,670 $0.00 Strike: $6.48 $0.00
Disclosure

SEC source: 0001144204-16-139501 · v455035_4.xml · derivative · entry 5

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,670 shares

Expires 2023-04-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 13, 2016 Filed Dec 14, 2016 16:35 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 Exercise / conversionCommon Stock 24,670 $6.48 $159,861.60
Disclosure

SEC source: 0001144204-16-139501 · v455035_4.xml · nonDerivative · entry 1

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 01, 2016 Filed Dec 7, 2016 20:55 UTC Accelerate Diagnostics, Inc AXDX · Entity 78156 Exercise / conversionStock Option (right to buy) · Derivative 20,000 $0.00 Strike: $6.48 $0.00
Disclosure

SEC source: 0001144204-16-138466 · v454647_4.xml · derivative · entry 5

PATIENCE JOHN · CIK 0001021413 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,670

Underlying: Common Stock · 20,000 shares

Expires 2023-04-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: The total number of stock options held by the reporting person was previously aggregated in Table II of the reporting person's previous Form 4s. The number of stock options reported on this Form 4 reflects only the number of stock options of the class reported herein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.